ClinicalTrials.gg
RecruitingNCT07680439Updated Nov 17, 2026

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

A Phase 2 interventional study of BCB-276 in Diffuse Intrinsic Pontine Glioma, DIPG and Brain Tumor, sponsored by BrainChild Bio, Inc. Recruiting at 6 sites in United States. Open to participants aged 1 Year to 26 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by BrainChild Bio, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 17, 2026Site recruiting status changedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
1 Year to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States — 23 open to participants now, 34 under way, none of them phase 3. Diffuse Intrinsic Pontine Glioma · United States.

Planned enrollment
13th of 82
75 · median 30
Started
2026
with 4 others
Phase 2
15 of 88
6 open now
Primary completion
2028-10
later than 21 of 33 live
Registered
88th of 88
by date

Among the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, this one is the 13th largest by planned enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 21 of the 33 other live ones, and was the 88th registered.

Diffuse Intrinsic Pontine Glioma

119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.

Browse Diffuse Intrinsic Pontine Glioma studies →

Open to participants now

23 of the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Diffuse Intrinsic Pontine Glioma studies recruiting now, 3 (11%) set no upper age limit and 25 (89%) stop at 75 or younger; 27 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 26 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG.

To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study.

BCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.

Read the detailed description

Diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive brainstem tumor that primarily affects children and has limited treatment options. Radiation therapy is the current standard of care and may provide temporary benefit, but new treatment approaches are needed.

This Phase 2 study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with DIPG after completion of initial standard radiation therapy. The study will assess survival, safety, and tumor response. All eligible participants will receive BCB-276, and outcomes will be compared with information from similar individuals with DIPG whose data have been collected in a registry.

To take part in this study, eligible patients must begin participation within 6 weeks after completing radiation therapy and must not have received prior anti-cancer therapy other than radiation with or without temozolomide. Participation includes collection of participant's white blood cells by leukapheresis, manufacturing of BCB-276 from the participant's own immune cells, and placement of a catheter or reservoir to deliver treatment directly into the fluid-filled spaces of the brain.

BCB-276 is given at participating research centers approximately every 2 weeks for a planned course of up to 15 doses over approximately 7-8 months. Study visits include treatment, safety monitoring, MRI scans, laboratory tests, and other assessments. Participants may be followed for up to approximately 2 years from the first BCB-276 treatment, and some follow-up visits may be conducted remotely. Because BCB-276 is investigational, side effects may occur and safety will be closely monitored.

03

Conditions studied

  • Diffuse Intrinsic Pontine Glioma
  • DIPG
  • Brain Tumor
  • CNS Tumor
  • Central Nervous System Tumor
  • Pediatric Cancer
  • Adult Cancer Patients
  • CNS Tumor, Childhood
  • CNS Tumor, Adult
  • Brainstem Glioma
  • Diffuse Midline Glioma
  • DMG

Keywords

  • BCB-276
  • B7-H3-specific Chimeric Antigen Receptor [CAR] T cell therapy
  • B7-H3
  • B7-H3 CAR T
  • B7-H3 CAR T Cells
  • Chimeric antigen receptor T cells
  • CAR T Cell
  • Immunotherapy
  • Cell Therapy
  • Pediatric
  • Children
  • Adolescent
  • Young Adult
  • Adult
04

Who can participate

Ages eligible
1 Year to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be aged 1 and ≤ 26 years and weigh ≥10kg.
  • Diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG) based on imaging, with or without confirmation consistent with high-grade glioma or diffuse midline glioma
  • Able to tolerate leukapheresis and other study procedures in the opinion of the Investigator.
  • Central Nervous System (CNS) reservoir catheter present prior to first dose of study drug.
  • Participant must have completed standard radiation therapy within 6 weeks of enrollment for participation.
  • Performance Status of ≥ 60; mild to moderate restriction or better. Lansky (under 16 years of age) or (16 years of age or older).
  • Adequate organ function and overall clinical status to participate, including stable or improving neurologic symptoms.
  • Participants of childbearing/fathering potential must agree to use highly effective from the time of enrollment through 12 months following the last T cell infusion.
  • Participants with ventriculoperitoneal (VP) shunts need to have a programable system and be able to tolerate temporary adjustment of the shunt required for study treatment.
  • Participant must meet all other health and safety criteria defined in the study protocol.
  • Participant and/or authorized legal representative willing to provide consent/assent for study participation, including participation in the 15-year long term follow up period.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Previous tumor-directed therapy or treatment-directed clinical study other than standard radiation with or without temozolamide.
  • Evidence of disease.
  • Requirement of high or increasing doses of prior to participation.
  • Severe swallowing difficulties or other significant clinical conditions that may interfere with participation.
  • Presence of an active other than DIPG.
  • Active or uncontrolled (HIV), , or infection based on protocol-required laboratory testing.
  • Pregnant or breastfeeding.
  • Presence of any condition that, in the Investigator's opinion, would prohibit the participant from undergoing treatment under this protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    BCB-276 CAR-T therapy for newly diagnosed DIPG patients post-radiation therapy

    Participants will receive up to 15 intraventricular administrations of BCB-276 delivered every 14 days (+/- 2 days) for an approximate total duration of 30 weeks.

    Biological: BCB-276

Interventions

  • BiologicalBCB-276

    Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant's own immune cells designed to target B7-H3. All eligible participants will receive up to 15 intraventricular administrations of BCB-276 every 2 weeks for an approximate total duration of 30 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Up to 24 months from date of enrollment

    Time frame: Overall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment).

Secondary outcomes

  1. Safety and Tolerability of BCB-276

    Incidence of adverse events, including serious adverse events, and adverse events leading to discontinuation of study treatment.

    Time frame: Up to 35 weeks from enrollment (28 days after last dose of BCB-276).

  2. Radiographic Response to BCB-276

    Measure the frequency of disease response (progressive disease, stable disease, partial response, complete response) based on MRI assessment per RANO criteria.

    Time frame: Up to 24 months from date of enrollment.

  3. Presence of BCB-276 in Cerebrospinal Fluid (CSF)

    Quantify the presence and amount of BCB-276 in CSF.

    Time frame: Up to approximately 30 weeks from first dose of BCB-276.

  4. Progression-Free Survival (PFS)

    PFS as measured by time in months, from date of diagnosis to first incidence of clinical or radiographically confirmed progression.

    Time frame: Up to approximately 24 months from date of enrollment.

07

Study locations

4 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Oct 2028, 25 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 2, 2026
StartActual
Sep 4, 2026was Aug 2026
Primary completionEst.
Oct 2028
CompletionEst.
Jul 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Children's Hospital of Philadelphia · Philadelphia, United StatesNot yet recruiting→Recruiting
  • Children's Healthcare of Atlanta · Atlanta, United StatesNot yet recruiting→Recruiting
  • Lurie Children's Hospital · Chicago, United StatesNot yet recruiting→Recruiting
across 3 updates, Oct 21, 2026 – Nov 17, 2026
Start date
Aug 2026→Sep 4, 2026 (actual)
Oct 21, 2026
Show all 3 updates
  1. Nov 17, 2026
    Lurie Children's Hospital is now Recruiting
    + 1 other change: verification date
  2. Oct 28, 2026
    Children's Healthcare of Atlanta is now Recruiting
  3. Oct 21, 2026
    Children's Hospital of Philadelphia is now Recruiting
    Start date Aug 2026→Sep 4, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07680439
Lead sponsor
BrainChild Bio, Inc
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Sep 4, 2026
Primary completion
Oct 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

BrainChild Bio Study Team
Contact
clinicaltrials@brainchildbio.com
425-569-8747
Cori Abikoff, MD
study director · BrainChild Bio, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion